ECSP105163A - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents

Composiciones farmaceuticas de agonista parcial de 5ht4

Info

Publication number
ECSP105163A
ECSP105163A EC2010005163A ECSP105163A ECSP105163A EC SP105163 A ECSP105163 A EC SP105163A EC 2010005163 A EC2010005163 A EC 2010005163A EC SP105163 A ECSP105163 A EC SP105163A EC SP105163 A ECSP105163 A EC SP105163A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
partial agonist
percent
weight
amount
Prior art date
Application number
EC2010005163A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP105163A publication Critical patent/ECSP105163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica sólida para administración oral, la cual comprende tegaserod en forma de base o de sal, en una cantidad de hasta el 10 por ciento en peso, un agente de volumen en una cantidad del 70 al 90 por ciento en peso, un desintegrante en una cantidad menor al 15 por ciento en peso, un abrillantador, y un lubricante.
EC2010005163A 2001-12-21 2010-06-16 Composiciones farmaceuticas de agonista parcial de 5ht4 ECSP105163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
ECSP105163A true ECSP105163A (es) 2010-07-30

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010005163A ECSP105163A (es) 2001-12-21 2010-06-16 Composiciones farmaceuticas de agonista parcial de 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (es)
EP (2) EP1321142A1 (es)
JP (1) JP4718776B2 (es)
KR (1) KR100980144B1 (es)
CN (1) CN100464749C (es)
AR (1) AR037937A1 (es)
AT (1) ATE320807T1 (es)
AU (1) AU2002361198B2 (es)
BR (1) BR0215148A (es)
CA (1) CA2470668C (es)
CO (1) CO5640102A2 (es)
CY (1) CY1105559T1 (es)
DE (1) DE60210139T2 (es)
DK (1) DK1458377T3 (es)
EC (1) ECSP105163A (es)
EG (1) EG24194A (es)
ES (1) ES2258171T3 (es)
HU (1) HU226589B1 (es)
IL (2) IL162451A0 (es)
MX (1) MXPA04006157A (es)
MY (1) MY139546A (es)
NO (1) NO20042779L (es)
NZ (1) NZ533585A (es)
PE (1) PE20030872A1 (es)
PL (1) PL369509A1 (es)
PT (1) PT1458377E (es)
RU (1) RU2322978C2 (es)
SI (1) SI1458377T1 (es)
TW (1) TWI260221B (es)
WO (1) WO2003053432A1 (es)
ZA (1) ZA200404467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ID28510A (id) * 1998-08-21 2001-05-31 Novartis Ag Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ATE399554T1 (de) * 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil

Also Published As

Publication number Publication date
EP1321142A1 (en) 2003-06-25
RU2322978C2 (ru) 2008-04-27
DE60210139D1 (de) 2006-05-11
EP1458377B1 (en) 2006-03-22
NZ533585A (en) 2006-04-28
HU226589B1 (en) 2009-04-28
PL369509A1 (en) 2005-04-18
BR0215148A (pt) 2004-10-19
ES2258171T3 (es) 2006-08-16
IL162451A (en) 2009-02-11
HUP0402492A3 (en) 2008-04-28
US20050106236A1 (en) 2005-05-19
ZA200404467B (en) 2006-05-31
CY1105559T1 (el) 2010-07-28
ATE320807T1 (de) 2006-04-15
TW200410684A (en) 2004-07-01
DK1458377T3 (da) 2006-06-12
MXPA04006157A (es) 2004-10-27
KR100980144B1 (ko) 2010-09-03
AU2002361198B2 (en) 2006-06-08
KR20040066922A (ko) 2004-07-27
JP2005516946A (ja) 2005-06-09
EG24194A (en) 2008-10-14
WO2003053432A1 (en) 2003-07-03
TWI260221B (en) 2006-08-21
RU2004122631A (ru) 2005-08-10
PE20030872A1 (es) 2003-11-24
MY139546A (en) 2009-10-30
PT1458377E (pt) 2006-07-31
US20090104263A1 (en) 2009-04-23
JP4718776B2 (ja) 2011-07-06
CO5640102A2 (es) 2006-05-31
IL162451A0 (en) 2005-11-20
CA2470668C (en) 2011-07-05
CN100464749C (zh) 2009-03-04
SI1458377T1 (sl) 2006-08-31
CA2470668A1 (en) 2003-07-03
CN1606438A (zh) 2005-04-13
AR037937A1 (es) 2004-12-22
NO20042779L (no) 2004-09-17
DE60210139T2 (de) 2006-08-17
HUP0402492A2 (hu) 2005-07-28
EP1458377A1 (en) 2004-09-22
AU2002361198A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
AR037937A1 (es) Composiciones farmaceuticas de agonista parcial de 5ht4
AR035074A1 (es) Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas
ECSP088239A (es) Composición de liberación de fármaco sostenida
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR037951A1 (es) Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
CO5390076A1 (es) Composiciones farmaceuticas
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
EA200400471A1 (ru) Оральная дозированная форма пропиверина
TW200517106A (en) Sustained release pharmaceutical compositions
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
HRP20090381T1 (en) Compositions comprising drospirenone molecularly dispersed
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BRPI0413676A (pt) composto, e, composição farmacêutica
UY27459A1 (es) Compuestos destinados a reducir la ingestión excesiva de alimento
AR070593A1 (es) Composiciones efervescentes
BR0318646A (pt) composição de branqueamento de dentes oral sólida
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
CY1113164T1 (el) Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral